NO20054743L - Guanidinderivater og anvendelse derav som neuropeptid FF reseptor antagonister - Google Patents
Guanidinderivater og anvendelse derav som neuropeptid FF reseptor antagonisterInfo
- Publication number
- NO20054743L NO20054743L NO20054743A NO20054743A NO20054743L NO 20054743 L NO20054743 L NO 20054743L NO 20054743 A NO20054743 A NO 20054743A NO 20054743 A NO20054743 A NO 20054743A NO 20054743 L NO20054743 L NO 20054743L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- pharmaceutically acceptable
- neuropeptide
- treatment
- guanidine derivatives
- Prior art date
Links
- 150000002357 guanidines Chemical class 0.000 title abstract 2
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract 2
- 102000011015 Neuropeptide FF receptor Human genes 0.000 title 1
- 108010061550 Neuropeptide FF receptor Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000004454 Hyperalgesia Diseases 0.000 abstract 1
- 208000035154 Hyperesthesia Diseases 0.000 abstract 1
- 229940122109 Neuropeptide FF receptor antagonist Drugs 0.000 abstract 1
- 206010057852 Nicotine dependence Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- UMKHUSRDQFQHAK-RNJMTYCLSA-N RF9 Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C12CC3CC(CC(C3)C1)C2)CCCNC(=N)N)C(N)=O)C1=CC=CC=C1 UMKHUSRDQFQHAK-RNJMTYCLSA-N 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 150000007514 bases Chemical class 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003792 electrolyte Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 230000006386 memory function Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000506 psychotropic effect Effects 0.000 abstract 1
- 230000010656 regulation of insulin secretion Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH4662003 | 2003-03-20 | ||
| PCT/CH2004/000175 WO2004083218A1 (de) | 2003-03-20 | 2004-03-22 | Guanidinderivate und ihre verwendung als neuropeptid ff rezeptor-antagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20054743L true NO20054743L (no) | 2005-10-14 |
Family
ID=32996985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054743A NO20054743L (no) | 2003-03-20 | 2005-10-14 | Guanidinderivater og anvendelse derav som neuropeptid FF reseptor antagonister |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7727979B2 (es) |
| EP (1) | EP1608662A1 (es) |
| JP (1) | JP2006520330A (es) |
| KR (1) | KR20050107611A (es) |
| CN (1) | CN100355758C (es) |
| AR (1) | AR043662A1 (es) |
| AU (1) | AU2004222224A1 (es) |
| BR (1) | BRPI0408357A (es) |
| CA (1) | CA2518679A1 (es) |
| CL (1) | CL2004000553A1 (es) |
| MX (1) | MXPA05009855A (es) |
| NO (1) | NO20054743L (es) |
| RU (1) | RU2337911C2 (es) |
| TW (1) | TW200510434A (es) |
| WO (1) | WO2004083218A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2004000553A1 (es) | 2003-03-20 | 2005-02-04 | Actelion Pharmaceuticals Ltd | Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende. |
| WO2005092871A2 (en) * | 2004-03-19 | 2005-10-06 | Dipharma S.P.A. | Intermediates for the preparation of pramipexole |
| WO2008008517A2 (en) | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | Bridged diazepan orexin receptor antagonists |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| EP2150114A4 (en) | 2007-05-18 | 2012-01-18 | Merck Sharp & Dohme | OXO-BRIDGED DIAZEPANOREXINE RECEPTOR ANTAGONISTS |
| UA99620C2 (en) | 2007-05-23 | 2012-09-10 | Мерк Шарп Энд Доме Корп. | Pyridyl piperidine orexin receptor antagonists |
| WO2008150364A1 (en) | 2007-05-23 | 2008-12-11 | Merck & Co., Inc. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| MX2015001500A (es) | 2012-08-02 | 2015-04-08 | Merck Sharp & Dohme | Compuestos antidiabeticos triciclicos. |
| AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US10344002B2 (en) | 2016-09-26 | 2019-07-09 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
| US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| CA3049464A1 (en) | 2017-02-14 | 2018-08-23 | Research Triangle Institute | Proline-based neuropeptide ff receptor modulators |
| CN112203673A (zh) * | 2018-03-09 | 2021-01-08 | 国家科学研究中心 | 混合μ阿片受体和神经肽FF受体结合分子、其制备方法及在治疗中的用途 |
| CN110093348B (zh) * | 2018-12-05 | 2022-11-29 | 西北工业大学 | 增强小鼠NPFFR2基因表达的shRNA |
| JP2022543460A (ja) | 2019-08-06 | 2022-10-12 | ドメイン・セラピューティクス | 神経ペプチドｆｆ受容体アンタゴニストとしての５－ヘテロアリール－ピリジン－２－アミン化合物 |
| CN112341404B (zh) * | 2019-08-09 | 2023-05-23 | 成都苑东生物制药股份有限公司 | 噻唑类衍生物或盐、异构体、其制备方法及用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620508A1 (de) * | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
| BE795257A (fr) | 1972-02-10 | 1973-08-09 | Thomae Gmbh Dr K | Nouveaux oxazols |
| GB8333514D0 (en) * | 1983-12-16 | 1984-01-25 | Erba Farmitalia | Tetrahydrothiazolo(5 4-c)pyridine derivatives |
| JPS60226810A (ja) | 1984-04-25 | 1985-11-12 | Ikeda Mohandou:Kk | 抗潰瘍剤 |
| GB2173187B (en) * | 1985-03-23 | 1988-05-18 | Erba Farmitalia | Condensed 2-substituted thiazole derivatives |
| JPS6233158A (ja) | 1985-08-02 | 1987-02-13 | Shionogi & Co Ltd | ベンズイミダゾ−ル誘導体および抗潰瘍剤 |
| WO1989005643A1 (en) * | 1987-12-18 | 1989-06-29 | Pfizer Inc. | Heterocyclic-substituted quinoline-carboxylic acids |
| KR0168978B1 (ko) * | 1995-07-12 | 1999-01-15 | 김종인 | 헤테로고리 접합 티아졸 유도체 |
| JPH0959258A (ja) * | 1995-08-11 | 1997-03-04 | Ono Pharmaceut Co Ltd | グアニジル誘導体 |
| FR2814367B1 (fr) * | 2000-09-25 | 2008-12-26 | Inst Nat Sante Rech Med | Ligands du recepteur npff pour le traitement de la douleur et des hyperalgies |
| CL2004000553A1 (es) | 2003-03-20 | 2005-02-04 | Actelion Pharmaceuticals Ltd | Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende. |
-
2004
- 2004-03-17 CL CL200400553A patent/CL2004000553A1/es unknown
- 2004-03-19 AR ARP040100923A patent/AR043662A1/es unknown
- 2004-03-19 TW TW093107426A patent/TW200510434A/zh unknown
- 2004-03-22 MX MXPA05009855A patent/MXPA05009855A/es unknown
- 2004-03-22 JP JP2006504158A patent/JP2006520330A/ja active Pending
- 2004-03-22 CA CA002518679A patent/CA2518679A1/en not_active Abandoned
- 2004-03-22 US US10/549,685 patent/US7727979B2/en not_active Expired - Fee Related
- 2004-03-22 EP EP04722212A patent/EP1608662A1/de not_active Withdrawn
- 2004-03-22 KR KR1020057016769A patent/KR20050107611A/ko not_active Application Discontinuation
- 2004-03-22 RU RU2005132308/04A patent/RU2337911C2/ru not_active IP Right Cessation
- 2004-03-22 WO PCT/CH2004/000175 patent/WO2004083218A1/de active Application Filing
- 2004-03-22 CN CNB2004800074476A patent/CN100355758C/zh not_active Expired - Fee Related
- 2004-03-22 BR BRPI0408357-1A patent/BRPI0408357A/pt not_active IP Right Cessation
- 2004-03-22 AU AU2004222224A patent/AU2004222224A1/en not_active Abandoned
-
2005
- 2005-10-14 NO NO20054743A patent/NO20054743L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7727979B2 (en) | 2010-06-01 |
| AR043662A1 (es) | 2005-08-03 |
| RU2337911C2 (ru) | 2008-11-10 |
| CN100355758C (zh) | 2007-12-19 |
| WO2004083218A1 (de) | 2004-09-30 |
| EP1608662A1 (de) | 2005-12-28 |
| CL2004000553A1 (es) | 2005-02-04 |
| BRPI0408357A (pt) | 2006-03-21 |
| MXPA05009855A (es) | 2005-12-06 |
| RU2005132308A (ru) | 2006-03-20 |
| KR20050107611A (ko) | 2005-11-14 |
| US20060194788A1 (en) | 2006-08-31 |
| JP2006520330A (ja) | 2006-09-07 |
| AU2004222224A1 (en) | 2004-09-30 |
| CA2518679A1 (en) | 2004-09-30 |
| CN1761673A (zh) | 2006-04-19 |
| TW200510434A (en) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20054743L (no) | Guanidinderivater og anvendelse derav som neuropeptid FF reseptor antagonister | |
| TW200716648A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| WO2007130075A8 (en) | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors | |
| WO2008024390A3 (en) | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders | |
| NO20083514L (no) | Heterobicykliske sulfonamidderivater for behandling av diabetes | |
| NO20091548L (no) | Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes | |
| WO2008094992A3 (en) | 2-aminopyridine derivatives useful as kinase inhibitors | |
| TNSN05320A1 (en) | Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors | |
| NO20085064L (no) | 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
| ATE427926T1 (de) | Cycloalkylaminderivate | |
| NO20054852L (no) | GFAT inhibitorer | |
| WO2009010416A3 (en) | Inhibitors of 11b-hydroxysteroid dehydrogenase | |
| NO20091893L (no) | Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav. | |
| WO2009102428A3 (en) | 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 | |
| EP2266569A3 (en) | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | |
| NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
| WO2007127635A3 (en) | Diketo-piperazine and piperidine derivatives as antiviral agents | |
| NO20083114L (no) | Polysykliske indazolderivater som er ERK-inhibitorer | |
| ATE400547T1 (de) | Anthranilsäurederivate, verfahren zu deren herstellung und deren verwendung als dhodh inhibitoren | |
| WO2007044085A3 (en) | Heteroaryl compounds and their uses as therapeutic agents | |
| WO2008017827A3 (en) | Azole and thiazole derivatives and their uses | |
| MX2009010731A (es) | Derivados de acido 1-(1-bencilpiperidin-4-il)benzimidazol-5-carbox ilico para el tratamiento de diabetes mellitus. | |
| SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| MY141972A (en) | Biaryloxymethylarenecarboxylic acids | |
| WO2009063202A3 (en) | Use of crth2 antagonist compounds |